Public Employees Retirement Association of Colorado Sells 1,022 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Public Employees Retirement Association of Colorado decreased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 1.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 53,305 shares of the company’s stock after selling 1,022 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Elanco Animal Health were worth $769,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ELAN. Benjamin F. Edwards & Company Inc. grew its stake in shares of Elanco Animal Health by 337.7% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after acquiring an additional 1,361 shares during the last quarter. nVerses Capital LLC purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $32,000. ORG Partners LLC bought a new stake in Elanco Animal Health during the 2nd quarter valued at about $31,000. Jones Financial Companies Lllp purchased a new position in Elanco Animal Health in the fourth quarter worth about $37,000. Finally, Global Financial Private Client LLC bought a new position in shares of Elanco Animal Health in the first quarter worth approximately $72,000. 97.48% of the stock is owned by institutional investors.

Analyst Ratings Changes

ELAN has been the topic of several analyst reports. Piper Sandler lowered their price objective on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Monday, July 1st. Barclays upped their price target on Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Monday. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $17.43.

Elanco Animal Health Trading Down 1.6 %

NYSE:ELAN opened at $13.66 on Thursday. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80. The business has a fifty day moving average price of $14.00 and a 200-day moving average price of $15.10. The firm has a market capitalization of $6.75 billion, a price-to-earnings ratio of -5.15, a price-to-earnings-growth ratio of 1.33 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.18 earnings per share. Sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons acquired 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now directly owns 145,000 shares in the company, valued at approximately $1,886,450. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director Michael J. Harrington acquired 3,500 shares of Elanco Animal Health stock in a transaction dated Thursday, August 22nd. The shares were purchased at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at approximately $1,204,245.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The disclosure for this purchase can be found here. Insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.